Research Article

BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy

Figure 7

BEZ235 significantly enhanced the antitumor effect of sorafenib in vivo by PI3K/mTOR double inhibition. (a) Tumor tissues of each group were collected after 28-day treatment of tumor-bearing mice. Tumor volume was expressed as . . (b) Antitumor efficacies of sorafenib, BEZ235, and the combination of sorafenib and BEZ235 in Huh7R tumor xenografts. (c) A portion of the tumor tissue was lysed to extract tissue proteins (PI3K110γ, p-Akt, p-mTOR, p-ULK1(555), p-Beclin1, Atg5, cleaved caspase 9, cleaved caspase 3, and cleaved PARP) for western blot analysis. Data are presented as , . , all versus SFB single-agent group. SFB: sorafenib; BEZ: BEZ235; SFB + BEZ: sorafenib combined with BEZ235.
(a)
(b)
(c)